검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | N-803 |
Overview Company | ImmunityBio, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Gastroesophageal Junction (GEJ) Cancers |
Overview Indication | Triple Negative Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | ADCC) and complement-dependent cytotoxicity (CDC) |
MoA Biomarker | biomarkers-based algorithm for risk prediction and diagnosis of advanced liver fibrosis: a multi-centre study |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer.. Resistance of gynecological cancers to immunotherapy is due to their ability to impair the cytotoxic activity of immune cells. One strategy to overcome this resistance is the combination of different types of immunotherapies with different mechanisms of action and… |
Clinical Primary efficacy | ORR 33% |
Clinical ORR | 80% |
Clinical Result source | ClinicalTrials.gov NCT02384954 |
Clinical Data Tier / Score | A · 24 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | N-803 |
Overview Company | ImmunityBio, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Gastroesophageal Junction (GEJ) Cancers |
Overview Indication | Triple Negative Breast Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
MoA Mechanism | ADCC) and complement-dependent cytotoxicity (CDC) |
MoA Biomarker | biomarkers-based algorithm for risk prediction and diagnosis of advanced liver fibrosis: a multi-centre study |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | IL 15 enhances preclinical efficacy of anti-core 1 O-glycans monoclonal antibody NEO-201 against human endometrial and ovarian cancer.. Resistance of gynecological cancers to immunotherapy is due to their ability to impair the cytotoxic activity of immune cells. One strategy to overcome this resistance is the combination of different types of immunotherapies with different mechanisms of action and… |
Clinical Primary efficacy | ORR 33% |
Clinical ORR | 80% |
Clinical Result source | ClinicalTrials.gov NCT02384954 |
Clinical Data Tier / Score | A · 24 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교